Jeff Ryckman, Associate Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared on X:
“Big PFS gain in PD-L1-negative NSCLC. OptiTROP-Lung06 (LBA66)
Randomized phase 3, 455 pts, 1L advanced nonsquamous NSCLC (PD-L1 TPS<1%, EGFR/ALK-negative): sac-TMT + pembro vs platinum/pemetrexed + pembro. mPFS 15.0 vs 5.7 mo (HR 0.49 (0.36–0.65), and OS HR 0.58 (0.38–0.88), still immature, but extremely promising!”
Title: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
Authors: Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui, Peng Chen, Hua Zhong, Yongsheng Wang, Zhangzhou Huang, Zhi Xu, Xiaorong Dong, Tienan Yi, Ying Hu, Qiming Wang, Bolin Chen, Hui Wang, Longhua Sun, Lang He, Wei Zheng, Yina Wang, Xiaochen Zhang, Yu Yao, Yongsheng Li, Zhe Yang, Feng Ye, Xia Song, Ming Zhou, Li Yin, Yan Qing, Xiaoping Jin, Junyou Ge, Caicun Zhou
You can also read:
OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab Outperforms Chemoimmunotherapy in PD-L1–Negative NSCLC
